Medigene’s lead candidate targeting the well-characterized cancer testis antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1) has shown to be highly expressed in a wide variety of cancer types. MDG1015 is a 3rd Generation NY-ESO-1 Targeted TCR-T Therapy – Sensitive, Specific TCR with a Favorable Safety Profile, Combined with a Switch Receptor.
MDG1015 displayed increased T cell functionality as means of secretion of multiple cytokines when compared to the Naked TCR (Figure 1).
Figure 1:
TCT-T functionality with MDG1015 vs. Naked TCR